

# KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

## Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)

April 7-11, 2019 • Beaver Run Resort • Breckenridge, Colorado, USA

Scientific Organizers: Christian Klein, Mark S. Cragg and Germaine Fuh

Supported by the Directors' Fund

Abstract & Scholarship Deadline: December 11, 2018 / Abstract Deadline: January 9, 2019 / Discounted Registration Deadline: February 6, 2019

### SUNDAY, APRIL 7

#### Arrival and Registration

### MONDAY, APRIL 8

#### Welcome and Keynote Session

**George D. Yancopoulos**, Regeneron Pharmaceuticals, Inc., USA  
*Target Identification and Developing Antibodies for Clinical Application*

**Jennifer R. Cochran**, Stanford University, USA  
*Emerging Strategies for Developing Next-Generation Protein Therapeutics*

#### Mechanisms of Action for Depleting Antibodies

**Mark S. Cragg**, University of Southampton, UK  
*Targeting B Cells with Antibodies: From Oncology to Autoimmunity*

**Falk Nimmerjahn**, Universitätsklinikum Erlangen, Germany  
*Optimal Formats for Target Cell Deletion*

#### Short Talk(s) Chosen from Abstracts

#### Workshop 1: Engineering (Bispecific) Antibodies

##### Short Talks Chosen from Abstracts

#### Antibody Engineering

**Janine Schuurman**, Genmab B.V., Netherlands  
*Engineering Non-Classical Antibody Formats*

**Feng Wang**, Institute of Biophysics, China  
*Engineering Antagonistic and Agonistic Antibodies*

**Germaine Fuh**, 23andMe, USA  
*Engineering Antibody Specificity and Stability Using Deep Sequencing*

#### Short Talk Chosen from Abstracts

#### Poster Session 1

### TUESDAY, APRIL 9

#### Bispecific and Engineered Antibodies for Cancer Immunotherapy

**Nai-Kong V. Cheung**, Memorial Sloan-Kettering Cancer Center, USA  
*Cancer Immunotherapy with Bispecific Antibodies*

**Christian Klein**, Roche, Switzerland  
*Engineering Bispecific Antibodies for Combination Cancer Immunotherapy*

**Marie H. Kosco-Vilbois**, NovImmune SA, Switzerland  
*Bispecific CD47 Antibodies for Treatment of Cancer and Autoimmunity*

**John R. Desjarlais**, Xencor, USA  
*Bispecific Antibodies for T Cell Recruitment and T Cell Activation*

#### Short Talk(s) Chosen from Abstracts

#### Antibodies for Infectious Diseases

**David D. Ho**, Aaron Diamond AIDS Research Center, USA  
*Novel Antibodies for HIV Therapy and Prevention*

**JoAnn A. Suzich**, MedImmune, USA  
*Antibodies for Prevention and Treatment of Viral Infections*

**Kartik Chandran**, Albert Einstein College of Medicine, USA  
*Catching Viruses in Endosome Using Bispecific Antibodies*

#### Short Talk Chosen from Abstracts

#### Poster Session 2

### WEDNESDAY, APRIL 10

#### Next Generation Antibody Drug Conjugates

**Ronit Mazor**, Medimmune, Inc., USA  
*Progress with Antibody Toxin Fusion Proteins and Overcoming Immunogenicity*

**Richard J. Gregory**, ImmunoGen Inc., USA  
*Optimizing the Activity of Antibody Drug Conjugates*

**John M. Lambert**<sup>†</sup>, ImmunoGen, Inc., USA  
*The Promise of ADCs: A Simple Concept, Difficult to Execute! Where Are We Now?*

**W. Michael Kavanaugh**, CytomX Therapeutics, Inc., USA  
*Probody Therapeutics: Antibody Pro-drugs Designed for Safer and More Effective Cancer Therapies*

#### Short Talk(s) Chosen from Abstracts

#### Delivering Antibodies into the Brain

**Joy Yu Zuchero**, Denali Therapeutics Inc, USA  
*Novel Approaches for Delivery of Antibodies into the Brain*

**Per-Ola Freskgård**, F. Hoffmann-La Roche, Switzerland  
*Crossing the Blood Brain Barrier with Antibodies to Access Brain Targets*

**Allan Jensen**, Lundbeck, Denmark  
*Antibody based Therapies for Neurodegenerative Diseases*

#### Short Talk Chosen from Abstracts

#### Poster Session 3

### THURSDAY, APRIL 11

#### Bispecific Antibodies and Antibody Like Molecules

**Christoph Rader**, The Scripps Research Institute, USA  
*Chemically Programmed Antibodies*

**James A. Ernst**<sup>†</sup>, Genentech, Inc., USA  
*A Novel Bispecific Antibody Mimetic of FGF21 for the Treatment of Metabolic Disease and NASH*

**Andreas G. Plückthun**, University of Zürich, Switzerland  
*Engineering DARPins for Delivery into Cells*

**Yvonne Y. Chen**, University of California, Los Angeles, USA  
*Engineering Next-Generation Chimeric Antigen Receptors*

#### Short Talk(s) Chosen from Abstracts

#### Workshop 2: Antibodies for Immunological Applications

# KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

## Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)

April 7-11, 2019 • Beaver Run Resort • Breckenridge, Colorado, USA

Scientific Organizers: Christian Klein, Mark S. Cragg and Germaine Fuh

Supported by the Directors' Fund

Abstract & Scholarship Deadline: December 11, 2018 / Abstract Deadline: January 9, 2019 / Discounted Registration Deadline: February 6, 2019

### Short Talks Chosen from Abstracts

#### Beyond Checkpoint Blockade: Novel Approaches for Immunotherapy

**Mikael C. I. Karlsson**, Karolinska Institutet, Sweden  
*Anti-Marco Antibodies in Tumor Immunotherapy*

**Sean Hua Lim**, University of Southampton, UK  
*Targeting CD27*

**Elaine M. Paul†**, GlaxoSmithKline, USA  
*GSK 3359609 a Non-Depleting IgG4 Anti-ICOS Antibody*

#### Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

### FRIDAY, APRIL 12

#### Departure